KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash & Equivalents (2016 - 2025)

BeOne Medicines (ONC) has disclosed Cash & Equivalents for 11 consecutive years, with $2.5 billion as the latest value for Q1 2025.

  • On a quarterly basis, Cash & Equivalents fell 9.91% to $2.5 billion in Q1 2025 year-over-year; TTM through Mar 2025 was $2.5 billion, a 9.91% decrease, with the full-year FY2024 number at $2.6 billion, down 17.16% from a year prior.
  • Cash & Equivalents was $2.5 billion for Q1 2025 at BeOne Medicines, down from $2.6 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $4.5 billion in Q2 2022 to a low of $191000.0 in Q3 2022.
  • A 5-year average of $2.0 billion and a median of $2.6 billion in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: tumbled 99.99% in 2022, then soared 1605835.08% in 2023.
  • BeOne Medicines' Cash & Equivalents stood at $328000.0 in 2021, then skyrocketed by 1179645.12% to $3.9 billion in 2022, then decreased by 18.03% to $3.2 billion in 2023, then fell by 17.16% to $2.6 billion in 2024, then fell by 4.22% to $2.5 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Cash & Equivalents are $2.5 billion (Q1 2025), $2.6 billion (Q4 2024), and $9.3 million (Q3 2024).